Claims
- 1. An inhibitor molecule that binds to C2a or the C2a portion of C2.
- 2. An inhibitor molecule that binds to C2a or the C2a portion of C2 and inhibits both the classical and the lectin complement pathways.
- 3. An inhibitor molecule that binds to the same epitope as the monoclonal antibody 175-62.
- 4. The inhibitor molecule of any one of claims 1, 2, or 3, wherein said molecule is an antibody or a homologue, analogue or fragment thereof, a peptide, an oligonucleotide, a peptidomimetic or an organic compound.
- 5. The inhibitor molecule of claim 4, wherein the antibody fragments are Fab, F(ab′)2, Fv or single chain Fv.
- 6. The inhibitor molecule of claim 5, wherein the antibody is monoclonal.
- 7. The monoclonal antibody of claim 6, wherein the antibody is a chimeric, Delmmunized™, humanized or human antibody.
- 8. A monoclonal antibody 175-62.
- 9. A cell line that produces the monoclonal antibody 175-62.
- 10. A pharmaceutical composition comprising the inhibitor molecule of claim 1 and a pharmacologically acceptable carrier, excipient, stabilizer, or diluent.
- 11. A method of inhibition of complement activation comprising administering an inhibitor molecule that binds C2a or the C2a portion of C2.
- 12. A method of inhibition of the classical and lectin complement pathways comprising administering an inhibitor molecule that binds C2a or the C2a portion of C2.
- 13. The method of claim 11, wherein the inhibition of complement activation is determined in vitro.
- 14. The method of claim 11, wherein the molar ratio of inhibitor molecule to C2 is less than or equal to 1:2.
- 15. A method of treating a disease or condition that is mediated by excessive or uncontrolled activation of the complement system comprising administering, in vivo or ex vivo, an inhibitor molecule according to any of claims 1 to 3, 8 or 10.
- 16. The method of claim 15, wherein the inhibitor molecule is administered by intravenous infusion, intravenous bolus injection, intraperitoneal, intradermal, intramuscular, subcutaneous, intranasal, intratracheal, intraspinal, intracranial, or orally.
- 17. A diagnostic method comprising the detection of the amount of C2 or C2a present in a sample with the inhibitor molecule of claim 4.
- 18. The diagnostic method of claim 17, wherein the inhibitor molecule is the monoclonal antibody 175-62.
Parent Case Info
[0001] This application claims priority to U.S. Provisional Application No. 60/191,429, filed on Mar. 23, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60191429 |
Mar 2000 |
US |